This trial is testing if rimegepant can prevent cluster headaches.
- Cluster Headache
1 Primary · 2 Secondary · Reporting Duration: Baseline, week of treatment (days 1-8)
2 Treatment Groups
Chronic Cluster Headache Subjects
1 of 2
Cluster Headache Subjects
1 of 2
10 Total Participants · 2 Treatment Groups
Primary Treatment: Rimegepant · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many research participants are involved in this endeavor?
"Indeed, the information located on clinicaltrials.gov attests to this trial's ongoing recruitment process; it was first posted September 7th 2022 and its most recent update occurred a day prior. The study calls for 10 participants from one medical centre." - Anonymous Online Contributor
Has Rimegepant been given the green light by the FDA?
"While there is evidence that rimegepant possesses a certain degree of safety, as judged by the Phase 2 clinical trial standards, it only achieved a score of 2. This indicates that further studies are necessary to demonstrate its efficacy." - Anonymous Online Contributor
Are there any patient slots available for this experimental trial currently?
"Yes, current information on clinicaltrials.gov points to the fact that this trial is presently enrolling individuals. It was initially posted in September 7th 2022 and updated most recently on July 6th 2022. The research team seeks 10 participants at a single site." - Anonymous Online Contributor